

Rec'd PTO

28 NOV 2005

Docket No: 25401-38

PATENT # 4

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop PCT; Commissioner for Patents; P.O. Box 1450; Alexandria, Virginia 22313-1450 on November 23, 2005.



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Ulf Gyllensten et al : Paper No.
Serial No.: 10/529,446 : Group Art Unit:
Filing Date: March 28, 2005 : Examiner:

For: **Method for Estimating the Risk of Carcinoma Development**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


In accordance with the provisions of 37 C.F.R. §§ 1.56 and 1.97-1.98, Applicants cite the references listed on the attached Form PTO-1449. Copies of the non-U.S. patent references are enclosed.

Since the present statement is submitted before the mailing of a first Office Action on the merits, no statement or fee under 37 C.F.R. §1.97 is required (37 C.F.R. §1.97(b)(1)).

Please charge any fee required in connection with this Statement to Deposit Account 04-1133.

Respectfully submitted,

By:



Holly D. Kozlowski
Registration No. 30,468
Attorney for Applicant(s)
DINSMORE & SHOHL LLP
1900 Chemed Center
255 East Fifth Street
Cincinnati, Ohio 45202
(513) 977-8568

ATTY. DOCKET 25401-38

SERIAL NO. 10/529,446

APPLICANT Ulf Gyllensten et al

FILING DATE March 28, 2005

GROUP

FOR Method for Estimating the Risk of Carcinoma Development

UNITED STATES LETTERS PATENT

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER ART (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

[illegible]

EXAMINER

DATE CONSIDERED _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1208730v1